{"name":"BioVersys AG","slug":"bioversys-ag","ticker":"","exchange":"","domain":"bioversys.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BV100 (300 mg)","genericName":"BV100 (300 mg)","slug":"bv100-300-mg","indication":"Serious bacterial infections caused by resistant gram-negative organisms (Phase 3 development)","status":"phase_3"},{"name":"BV100 plus Polymyxin B","genericName":"BV100 plus Polymyxin B","slug":"bv100-plus-polymyxin-b","indication":"Bacterial infections","status":"phase_2"},{"name":"MEROPENEM 2 grams TID","genericName":"MEROPENEM 2 grams TID","slug":"meropenem-2-grams-tid","indication":"Bacterial infections (specific indication under investigation by BioVersys SAS in Phase 3)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Best Available Therapy (BAT)","genericName":"Best Available Therapy (BAT)","slug":"best-available-therapy-bat","indication":"Other","status":"phase_3"},{"name":"HRZE plus AlpE625","genericName":"HRZE plus AlpE625","slug":"hrze-plus-alpe625","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BV100 (300 mg)","genericName":"BV100 (300 mg)","slug":"bv100-300-mg","phase":"phase_3","mechanism":"BV100 is a benzoxaborole antibiotic that inhibits bacterial leucyl-tRNA synthetase, disrupting protein synthesis in susceptible pathogens.","indications":["Serious bacterial infections caused by resistant gram-negative organisms (Phase 3 development)"],"catalyst":""},{"name":"BV100 plus Polymyxin B","genericName":"BV100 plus Polymyxin B","slug":"bv100-plus-polymyxin-b","phase":"phase_2","mechanism":"BV100 targets the bacterial cell membrane, disrupting its integrity and leading to cell death, in combination with Polymyxin B, an antibiotic that targets the bacterial cell wall.","indications":["Bacterial infections"],"catalyst":""},{"name":"Best Available Therapy (BAT)","genericName":"Best Available Therapy (BAT)","slug":"best-available-therapy-bat","phase":"phase_3","mechanism":"BAT is a best available therapy comparator arm used in clinical trials, not a drug with its own mechanism of action.","indications":[],"catalyst":""},{"name":"HRZE plus AlpE625","genericName":"HRZE plus AlpE625","slug":"hrze-plus-alpe625","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MEROPENEM 2 grams TID","genericName":"MEROPENEM 2 grams TID","slug":"meropenem-2-grams-tid","phase":"phase_3","mechanism":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Bacterial infections (specific indication under investigation by BioVersys SAS in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZktkalJBZUNKYjlmNXlrcHo1NDBidEJPZ2R0SUlyVksxZGZ0YWhzTTJoTE1GTU56Mno0UzZNS3pUTTczV0JSbS13Q00tMnpyM1hkcU9TbFVNSU9ydXpwUmd3Y0NhVXZGYUxXZzJIQVphM2lsX3NMLWhwX1RKZ05yOVFsNEtZWmx4M1o2V2N6X2ZiNXlHQkdnbA?oc=5","date":"2026-04-07","type":"pipeline","source":"AD HOC NEWS","summary":"BioVersys AG / CH0210362643 - AD HOC NEWS","headline":"BioVersys AG / CH0210362643","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNNF90d1lHb0RvdnJDcjdrQUVxMXh0elI2SzI5elZGdm0wZnFzVTM3d0NQdGpfZ0lUTUc2TmhtbEtMT1o5b2l2dDZFS0xZQVljNmQxVURPUWRPQmFEdTIwMkNSeUlMNkhlQjFER3NjeUdrSmdJVWltc2tLT0R1WTJQOGV2ZU1OcmlERmtyaTQzcWtYejA0WXVSRGRkNXU?oc=5","date":"2025-11-06","type":"pipeline","source":"BioCentury","summary":"Recursion picks J&J alum Khan to succeed Gibson as CEO - BioCentury","headline":"Recursion picks J&J alum Khan to succeed Gibson as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPYjF1NkVPbjh3U2Vlcm9DbnpiMXB1dUZEZVBxRHhDVXVoT0VCc2Q3blhtemlvMEVmU2FOMzFLQTI0bHNiQjBDWURHMEZ1NDl1U2pseC1vbzRTZl9lM2VHSzdZYUROd0lldTF2ZWJpTHE4MWp0UUtHZ2paUHc5b1VTM0FpMHE1dUI5c2V1YWJrMXNmY0daNHRNQm9zUHdTUHM?oc=5","date":"2025-10-31","type":"pipeline","source":"startupticker.ch","summary":"More than 20 Swiss biotech companies to exhibit at Bio Europe - startupticker.ch","headline":"More than 20 Swiss biotech companies to exhibit at Bio Europe","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-27","type":"pipeline","source":"simplywall.st","summary":"Is BioVersys (VTX:BIOV) A Risky Investment? - simplywall.st","headline":"Is BioVersys (VTX:BIOV) A Risky Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE91QWljZEVZaFJmRk9QSVhYMk5HUXBhNExoR29QbVlSUzlKT251N3RudGJSeEd2RElvUVNnYTBFdWZOa1RyY3BKTnFPZ25JZmZiYXk1WGFiUmVqTDh0Zjd5ZU05NEVJT2ltTWVJRGo1TGtWWkJiRmZrdkxqa0NsLW8?oc=5","date":"2025-07-21","type":"pipeline","source":"BioXconomy","summary":"Eyes on Asia: Chugai, Mabwell, Shionogi - BioXconomy","headline":"Eyes on Asia: Chugai, Mabwell, Shionogi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOTFdsUUVCb0JBTGdYWFpDUGlzZndObG9MbGFPUDZaQk9pR1o1d1gyYkladFc1MGVQeWJmdms5Qm5tZGVOY2lKOVdwaXdCd3NPZGNtY2hYLUVqXzdwdW1NaDY0TVRUWGF4VGVlTldGQ0FWT0xBZG9UbjRvajdFdWEyeGVuMVRVeHZIS01tQTdzYzhNTUhRWHZhZnNZZ09QMXkwRFhUbThJUHJ2eDNfaFlSR2l0Nkg?oc=5","date":"2021-04-14","type":"pipeline","source":"European Pharmaceutical Review","summary":"EU to support novel antibiotics with €20 million funding - European Pharmaceutical Review","headline":"EU to support novel antibiotics with €20 million funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxONnR1eC1kV3ktM0I5a20wTFFpM08tcWI1MTVhaXRGNmpRQ3ZSUFIwWXZsNWRKcG5ydWdZUzAxUmV1Zk8zOTV4S0ZXdU9WQ2JobDV4YWlLRnItbUNnd2Z3YzZlSkNMdVRhTHRPelF3MThjbGJxQmhzbkF0eEg0SlJQQzZpa09XVU55NWZoc1RmNnh3MFl6b0oxcGM2cllxY3lET1BLRElXM0FHMnJpaGZGSG1jeUdZYU10V3JuOHRHT3VQVmUteUpr?oc=5","date":"2021-04-14","type":"pipeline","source":"BioSpectrum Asia","summary":"BioVersys receives €20M in EU financing to support new antibiotics development - BioSpectrum Asia","headline":"BioVersys receives €20M in EU financing to support new antibiotics development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1vbXlNRTc1UmJJcmdialNITHlGcWM3anNvMGRqQlF0bGdWN3RmTWJTaVFtNnNHRzN1d3FFN1Y4WFZ5V2Jzd3FCcEJVTXBzUWpPRnBZa253ZEl3R2pMYktreDVIUTRxczF1bk83ZTJIXzV6UQ?oc=5","date":"2021-01-07","type":"pipeline","source":"Straits Research","summary":"Pneumonia Therapeutics Market Size, Share & Growth Report by 2034 - Straits Research","headline":"Pneumonia Therapeutics Market Size, Share & Growth Report by 2034","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}